Navigation Links
Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
Date:2/6/2009

CAMBRIDGE, Mass. and LONDON, Feb. 6 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) and GlaxoSmithKline (GSK) today announced the execution of a license agreement granting GSK exclusive worldwide rights to IDX899. IDX899 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) in Phase II clinical development being developed by Idenix for the treatment of HIV/AIDS. New NNRTIs are needed to address the increasing prevalence of viral resistance and side effects associated with this drug class. To date, IDX899 has demonstrated high potency with low milligram doses, a high barrier to drug resistance, favorable risk/benefit profile, and the convenience of once-a-day administration.

Under the terms of the agreement, GSK will assume all development responsibility and associated costs for IDX899, and Idenix will receive an upfront payment of $34 million and will be eligible to receive up to $416 million in development, regulatory and sales milestones. Furthermore, if IDX899 is successfully developed and commercialized, Idenix will receive double-digit, tiered worldwide royalties.

"GSK, with a well-established HIV franchise and substantial drug development experience, is the ideal collaborator to help maximize the potential of IDX899," said Jean-Pierre Sommadossi, Chief Executive Officer of Idenix. "For Idenix, the significant value created through the license of IDX899 enables us to focus all of our resources on advancing our core strategic HCV assets, which include drug candidates from the three major classes of direct-acting HCV antivirals."

"IDX899 may play a significant role in improving treatment options for people with HIV/AIDS," commented Zhi Hong, Senior Vice President of the Infectious Diseases Centre of Excellence for Drug Discovery (ID CEDD) at GSK. "A once-daily, lower-dose
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
2. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
3. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
4. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
5. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
7. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
8. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
9. Alseres Pharmaceuticals Completes Enrollment in First Stage of the Altropane(R) POET-2 Phase III Program
10. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
11. Access Pharmaceuticals Presents new Combination Data on the Companys Angiolix(R) Therapeutic Monoclonal Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ... "Immunoprotein Diagnostic Testing Market - Forecasts to 2019: ... 6% and is expected to be valued at ... http://photos.prnewswire.com/prnh/20130307/600769 ... been segmented according to immunoprotein types which include ...
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... the second half of this yearBERLIN and TARRYTOWN, N.Y., ... Inc. (Nasdaq: REGN ) today announced that ... VEGF Trap-Eye, an investigational agent for the treatment of ... (CRVO). The companies plan to initiate a Phase 3 ...
... Investing in New Product Presentations for PatientsSAN DIEGO and ... AMLN ) and Eli Lilly and Company (NYSE: ... have agreed in principle to the terms of a ... device. Separately, the companies announced that they have initiated ...
Cached Medicine Technology:Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 2Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 3Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 4Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 2Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 3Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 4Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 5Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 6Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly 7
(Date:7/12/2014)... recent article released by Seattle's well known plastic surgeon, Dr. ... cosmetic surgical procedures in summer months . , ... to enliven the rainy Pacific Northwest, many people are turning ... work out as much during the winter as they had ... people eager to look their best for their summer vacations, ...
(Date:7/12/2014)... July 12, 2014 Wright & Schulte LLC, ... in Just For Men Lawsuits (case #59776/2014), announces they ... of reports that allege the popular hair dye, Just For ... to their face, neck and other areas. In addition to ... Men chemical burns , the advertisements being run by Wright ...
(Date:7/12/2014)... Floor-grade instrument buyers ... of 5. This above-average score represents favorable conditions ... negotiation power over the three years to 2014. ... the period, surging demand for healthcare services and ... product development, have placed upward pressure on the ...
(Date:7/12/2014)... 12, 2014 The largest pure occupational ... pleased to announce that it will be opening its ... facility will join four Atlanta-based Nova Medical Centers’ locations. ... 3209 Deans Bridge Road, and will be open from ... , “With Nova’s treatment philosophy of rapid return-to-work and ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 2Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 3Health News:Just for Men Lawsuit News: TV Campaign Launched by Wright & Schulte LLC to Inform Consumers of the Alleged Association between the Popular Hair Dye and Chemical Burns 4Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... cause infections that typically target the digestive tract or bowel; ... could result. Enterococcus also can invade the bloodstream, ... the heart valve. Typically the only people who become ill ... have health issues, such as diabetes or chronic kidney failure. ...
... Jenifer Goodwin HealthDay Reporter , WEDNESDAY, Nov. 16 ... at heightened risk for stroke, a new study suggests. ... the Nurses, Health Study and about 28,000 men from the ... 26 years. Over that time, both men and women ...
... found that flu strains migrate back and forth between different ... contrary to the common belief that flu strains from the ... The research appeared online on Nov. 14 in the ... supported in part by the Centers of Excellence for ...
... imaging (MRI) to evaluate cardiovascular risk in World Trade ... of Medicine have found that the responders who experienced ... on September 11, 2001, demonstrate high-risk features of atherosclerosis ... American Heart Association,s Scientific Sessions 2011 in Orlando, Florida. ...
... Medicine have identified hepcidin, a hormone that regulates iron ... treating atherosclerosis. Suppressing hepcidin is a way to ... found in arterial plaques. Reducing iron levels pushes those ... called "reverse cholesterol transport," interfering with atherosclerosis, researchers have ...
... HealthDay Reporter , TUESDAY, Nov. 15 (HealthDay News) -- First ... following the New York City terror attacks on Sept. 11, ... Those Ground Zero workers who got there first may ... who came on the scene after Sept. 13, and may be ...
Cached Medicine News:Health News:Wayne State University to study novel treatment for antibiotic-resistant bacteria 2Health News:Blood Type May Be Associated With Stroke Risk: Study 2Health News:NIH grantees rebut theory that seasonal flu strains originate in tropical regions 2Health News:NIH grantees rebut theory that seasonal flu strains originate in tropical regions 3Health News:WTC workers exposed earlier to dust cloud have higher risk of atherosclerotic lesions 2Health News:Hormone that controls iron levels may be target for atherosclerosis treatment 2Health News:9/11 First Responders May Face Greater Heart Risks 2Health News:9/11 First Responders May Face Greater Heart Risks 3
This a new dedicated VICTOR2 model for fluorescence, fluorescence polarization and luminescence measurement with stacker and robotic loading....
This a new dedicated VICTOR2 model for fluorescence and luminescence detection with stacker and robotic loading....
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... multimode readers offering 96-channel parallel detection of ... and 1,536-well microtiter plates. Compact workstations ... for the transport of microtiter plates with ... day. The need for mechanical switching required ...
Medicine Products: